Non-Hodgins lymphoma treatment approved

Israel’s Teva has received US FDA approval for its Truxima treatment for several conditions of the deadly non-Hodgkin’s lymphoma, a type of blood cancer. Truxima is a bio-similar (tested low-cost alternative) to Rituxan (Rituximab) manufactured by Roche.,7340,L-3750979,00.html

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *